Evidence map›Paper›PMID 38255199›Full record

ArticleBiomedicines2024

Chemokine Receptor Antagonists Prevent and Reverse Cofilin-Actin Rod Pathology and Protect Synapses in Cultured Rodent and Human iPSC-Derived Neurons.

Thomas B Kuhn, Laurie S Minamide, Lubna H Tahtamouni, Sydney A Alderfer, Keifer P Walsh, Alisa E Shaw, Omar Yanouri, Henry J Haigler, Michael R Ruff, James R Bamburg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Thomas B KuhnDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
Laurie S MinamideDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
Lubna H TahtamouniDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
Sydney A AlderferDepartment of Chemical and Biological Engineering and School of Biomedical Engineering, Colorado State University, Fort Collins, CO 80523, USA.
Keifer P WalshDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0001-7944-4437
Alisa E ShawDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.
Omar YanouriMolecular, Cellular and Integrative Neuroscience Program, Colorado State University, Fort Collins, CO 80523, USA.
Henry J HaiglerCreative Bio-Peptides, Inc., 10319 Glen Road, Suite 100, Potomac, MD 20854, USA.
Michael R RuffCreative Bio-Peptides, Inc., 10319 Glen Road, Suite 100, Potomac, MD 20854, USA.ORCID 0000-0002-2632-4594
James R BamburgDepartment of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CO 80523, USA.ORCID 0000-0003-3767-3586
Colorado State University · USHashemite University · JO

Funding

Initiative to Maximize Student Development in Translational MedicineT32GM144856 · NIGMS · COLORADO STATE UNIVERSITY · PI MARK D ZABEL · 2022 to 2026
$2.3M
PrPC- and NOX-dependent signaling in dementiaR01AG049668 · NIA · COLORADO STATE UNIVERSITY · PI BAMBURG, JAMES R · 2015 to 2019
$1.5M
Optimization of a Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's DiseaseR43AG074715 · NIA · CREATIVE BIO-PEPTIDES, INC. · PI RUFF, MICHAEL R · 2021 to 2021
$500k
Development of a Novel Chemokine Receptor Antagonist Peptide as a Synapse Protecting Treatment for Neurodegeneration in Alzheimer's DiseaseR43AG071064 · NIA · CREATIVE BIO-PEPTIDES, INC. · PI RUFF, MICHAEL R · 2020 to 2020
$449k
Fluorescence Microscope for Automated Large Array Scanning and 3D imagingS10OD025127 · OD · COLORADO STATE UNIVERSITY · PI BAMBURG, JAMES R · 2018 to 2018
$188k
NIA NIH HHS R01 AG049668NIA NIH HHS R43 AG071064NIA NIH HHS R43 AG074715NIGMS NIH HHS T32 GM144856NIH HHS 1R43AG071064, 1R43AG074715, 1R01AG049668, 1S10OD025127NIH HHS S10 OD025127
6 · The paper itself

Abstract

Synapse loss is the principal cause of cognitive decline in Alzheimer's disease (AD) and related disorders (ADRD). Synapse development depends on the intricate dynamics of the neuronal cytoskeleton. Cofilin, the major protein regulating actin dynamics, can be sequestered into cofilactin rods, intra-neurite bundles of cofilin-saturated actin filaments that can disrupt vesicular trafficking and cause synaptic loss. Rods are a brain pathology in human AD and mouse models of AD and ADRD. Eliminating rods is the focus of this paper. One pathway for rod formation is triggered in ~20% of rodent hippocampal neurons by disease-related factors (e.g., soluble oligomers of Amyloid-β (Aβ)) and requires cellular prion protein (PrP

Indexed as

amyloid-βchemokine/cytokine receptor antagonistscofilactin rodsDAPTAHIV gp120human iPSC-derived neuronsIL-6neurodegenerative proteinopathiespeptide-Tprion-dependent lipid rafts

Identifiers

PMID38255199
PMCPMC10813319
OpenAlexW4390482807

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.